#China #Suzhou #biopharmaceuticals #Altruist Biologics #EMA Certification

Altruist Biologics Marks Major Milestone with EMA GMP Certification

Altruist Biologics, a leading contract development and manufacturing organization (CDMO) and fully owned subsidiary of Innovent Biologics, recently announced a significant achievement. The company's commercial manufacturing facility in Suzhou, China, has passed a rigorous inspection by the European Medicines Agency (EMA), earning the coveted Good Manufacturing Practice (GMP) certification without any critical findings. This essential certification opens the doors for the company to commercially market its biologics in the European market, a vital step for its ongoing global expansion efforts.

This EMA GMP certification is a pivotal moment for Altruist, confirming the facility's commitment to maintaining high-quality standards throughout the biologics manufacturing process. The detailed inspection covered all aspects of the biologics manufacturing lifecycle, which included a thorough evaluation of the facility's systems for quality assurance and its overall operational performance. Notably, the EMA acknowledged Altruist's stringent quality management frameworks, robust infrastructure, and superior technical capabilities.

Dr. Kaisong Zhou, the Chairman and CEO of Altruist Biologics, expressed his pride in this achievement and emphasized the importance of quality in every phase of biologics development. He stated, "Quality spans the entire biologics lifecycle, ensuring compliance with rigorous regulatory requirements from development through commercialization." He further highlighted that as innovative drug companies grapple with navigating complex international regulations and technology transfer challenges, Altruist is dedicated to maintaining high standards to enable medical innovations globally.

The Suzhou facility, recognized for its operational excellence, boasts 60,000 liters of antibody manufacturing capacity and is equipped to handle a variety of products, including antibodies, fusion proteins, and antibody drug conjugates. Furthermore, the company operates another site in Hangzhou, which has a total antibody manufacturing capacity of 172,000 liters. This site features four 20,000-liter stainless steel bioreactors, with plans for a new 2,000-liter antibody production line expected to be operational by mid-2027. Collectively, Altruist aims to reach a total operational capacity of 232,000 liters, positioning itself as one of the top ten biologics CDMOs in the industry.

With recognized facilities not only in China but also compliant with global standards set by regulatory bodies such as the U.S. FDA and Japan's PMDA, Altruist's commitment to quality extends across all its operations. The Suzhou site has successfully passed numerous inspections and audits by clients and regulatory authorities alike, reinforcing its reputation as a trustworthy partner in the biopharmaceutical landscape. The company's proactive commitment towards quality risk management has proved pivotal in minimizing compliance risks and uncertainties during technology transfers—ensuring that innovative therapies reach the global market more seamlessly.

This milestone underscores Altruist Biologics' goal of supporting biotech companies worldwide by providing reliable CDMO services for high-quality biopharmaceuticals. As regulatory landscapes grow increasingly challenging, Altruist aims to facilitate the timely access of innovative therapies to patients around the globe. Altruist's successful track record includes supporting the commercialization of over 20 drugs and achieving a remarkable success rate of over 99.8% in completed commercial batches.

In conclusion, the EMA GMP certification for Altruist’s Suzhou facility marks not just a validation of its quality processes, but also a commitment to overcoming geographic and regulatory barriers that impede the speed at which revolutionary therapies can reach patients. With a dedicated team of over 1,400 professionals, including top experts in biopharmaceutical production, Altruist Biologics is poised for continued growth and impact in the global healthcare sector.